Payload Information
General Information of This Payload
| Payload ID | PAY0VFGCR |
|||||
|---|---|---|---|---|---|---|
| Name | Methotrexate |
|||||
| Synonyms |
Methotrexate; 59-05-2; Amethopterin; Rheumatrex; Methylaminopterin; Abitrexate; Ledertrexate; Metatrexan; Hdmtx; Trexall; Mexate; Methylaminopterinum; Methotrexatum; Antifolan; Rasuvo; Folex; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Amethopterine; Metotrexato; Maxtrex; 4-Amino-10-methylfolic acid; Methotrexate hydrate; A-Methopterin; L-Amethopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; NSC-740; Methotrexate, L-; Medsatrexate; Methoblastin; Methotextrate; Methotrexat; Metotressato; Brimexate; Emthexat; Emthexate; Fauldexato; Lantarel; Lumexon; Metrotex; Novatrex; Otrexup; Tremetex; Trexeron; Trixilem; Texate; Metex; Mexate-Aq; NCI-C04671; CL-14377; N-Bismethylpteroylglutamic acid; Farmitrexat; Methoxtrexate; 133073-73-1; Methotrexate Lpf; Metotressato [DCIT]; Emtexate; CCRIS 1109; Nordimet; Xatmep; EMT 25,299; METHOTREXATE SODIUM; HSDB 3123; NSC 740; CL 14377; UNII-YL5FZ2Y5U1; [3H]methotrexate; Methotrexatum [INN-Latin]; Metotrexato [INN-Spanish]; EINECS 200-413-8; YL5FZ2Y5U1; [3H]-methotrexate; R 9985; REDITREX; NSC740; DTXSID4020822; 4-Aminomethylpteroylglutamic acid; CHEBI:44185; AI3-25299; TCMDC-125858; X 133; ADX-2191; MPI-2505; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid; WR-19039; CHEMBL34259; DTXCID80822; 4-Amino-N(sup 10)-methylpteroylglutamic acid; R-9985; Kyselina 4-amino-N(sup 10)-methylpteroylglutamova; Methotrexate [USAN:INN:BAN:JAN]; L-Glutamic acid, N-(4-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-; N-(4-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)-L-glutamicacid; N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid; CL14377; Kyselina 4-amino-N(sup 10)-methylpteroylglutamova [Czech]; Methotrexate [USAN:USP:INN:BAN:JAN]; NCGC00025060-04; C20H22N8O5; 4-amino-N(10)-methylpteroylglutamic acid; Mexate-Aq Preserved; N-(p-(((2,4-Diamino-6-pteridyl)methyl)methylamino)benzoyl)glutamic acid; Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)methylamino)benzoyl)-L-glutamova; METHOTREXATE (IARC); METHOTREXATE [IARC]; (2S)-2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioic acid; Glutamic acid, N-(p-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-, L-; Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)methylamino)benzoyl)-L-glutamova [Czech]; L-(+)-N-(p-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)glutamic acid; N-(p-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)-L-(+)-glutamic acid; N-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)carbonyl]-L-glutamic acid; METHOTREXATE (MART.); METHOTREXATE [MART.]; METHOTREXATE (USP-RS); METHOTREXATE [USP-RS]; Methotrexate, d-; METHOTREXATE (EP MONOGRAPH); METHOTREXATE (USP IMPURITY); METHOTREXATE [EP MONOGRAPH]; METHOTREXATE [USP IMPURITY]; METHOTREXATE (USP MONOGRAPH); METHOTREXATE [USP MONOGRAPH]; MLS001401431; Methotrexate Preservative Free; Methotrexate (hydrate); SMR000112001; folic acid antagonist; SR-01000075682; SMR000449324; METHOTREXATE SODIUM PRESERVATIVE FREE; Metolate; methotrexat-; Intradose-MTX; 1dhi; 1dhj; 2drc; 4-Amino-N10-methylpteroylglutamic acid; 4ocx; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]pentanedioic acid; L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-; N-(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)-L-glutamic acid; N-{4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl}-L-glutamic acid; CAS-59-05-2; Prestwick_322; Otrexup (TN); Xatmep (TN); JYLAMVO; L-METHOTREXATE; OTREXUP PFS; Methylaminopterin; MTX; Intrathecal methotrexate; Spectrum_001836; Tocris-1230; 4kn0; Prestwick0_000135; Prestwick1_000135; Prestwick2_000135; Spectrum2_001077; Spectrum3_000497; Spectrum4_000616; Spectrum5_000958; Abitrexate (Methotrexate); Methotrexate - Abitrexate; METHOTREXATE [MI]; METHOTREXATE [INN]; METHOTREXATE [JAN]; D07ALU; D0D3DU; D0SV8E; L(+)-Amethopterin hydrate; METHOTREXATE [HSDB]; METHOTREXATE [INCI]; METHOTREXATE [USAN]; NCIMech_000767; SCHEMBL3711; METHOTREXATE [VANDF]; Methotrexate hydrate (1:x); BIDD:PXR0175; Lopac0_000020; KBioGR_001172; KBioSS_002341; Methotrexate Methylaminopterin; MLS000049968; MLS002154208; DivK1c_000114; METHOTREXATE [WHO-DD]; METHOTREXATE [WHO-IP]; SPBio_001094; SPBio_002149; Amethopterin (hydrate); CL14377 (hydrate); WR19039 (hydrate); AMY235; cid_126941; cid_165528; GTPL4674; GTPL4815; SCHEMBL12421860; SCHEMBL23111732; BDBM18050; BDBM66082; HMS500F16; KBio1_000114; KBio2_002338; KBio2_004906; KBio2_007474; KBio3_001493; Methotrexate (JP17/USP/INN); L01BA01; L04AX03; FBOZXECLQNJBKD-ZDUSSCGKSA-N; g301; NINDS_000114; Bio1_000486; Bio1_000975; Bio1_001464; HMS1568K12; HMS2095K12; HMS2233O18; HMS3260C21; HMS3414L09; HMS3678L07; HMS3712K12; METHOTREXATE [ORANGE BOOK]; APC-2002; BCP13701; DRG-0024; GLUTAMIC ACID, N-(P-(((2,4-DIAMINO-6-PTERIDINYL)METHYL)METHYLAMINO)BENZOYL)-, L-(+)-; MPI-5004; Methotrexate [USAN:BAN:INN:JAN]; Tox21_110944; Tox21_300269; Tox21_500020; CCG-35800; EMT-25299; LS-249; METHOTREXATUM [WHO-IP LATIN]; MFCD00064370; s1210; STL535338; (4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzoyl)-L-glutamic acid; AKOS016340329; Tox21_110944_1; CS-1732; DB00563; KS-5093; LP00020; SDCCGSBI-0050009.P003; WR19039; IDI1_000114; SMP2_000020; (methyl)amino)benzamido)pentanedioic acid; NCGC00025060-01; NCGC00025060-02; NCGC00025060-03; NCGC00025060-05; NCGC00025060-06; NCGC00025060-07; NCGC00025060-08; NCGC00025060-09; NCGC00025060-10; NCGC00025060-11; NCGC00025060-12; NCGC00025060-13; NCGC00025060-15; NCGC00025060-16; NCGC00254216-01; NCGC00260705-01; HY-14519; EU-0100020; SW198601-3; Methotrexate 1.0 mg/ml in Dimethyl Sulfoxide; A10021; C01937; D00142; EN300-119523; Q422232; SR-01000597411; W-60383; (S)-2-(4-(((2,4-diaminopteridin-6-yl)methyl); Q-201366; SR-01000075682-1; SR-01000075682-2; SR-01000075682-6; SR-01000597411-1; W-105347; BRD-K59456551-001-09-3; BRD-K59456551-001-11-9; WLN: T66 BN DN GN JNJ CZ EZ H1N1&R DVMYVQ2VQ; Z1521553982; 4-AMINO-4-DEOXY-N(SUP 10)-METHYLPTEROYLGLUTAMATE; N,N,N,N-ETHYLENEDIAMINETETRA(METHYLENEPHOSPHONICACID); Methotrexate, European Pharmacopoeia (EP) Reference Standard; Methotrexate, United States Pharmacopeia (USP) Reference Standard; Glutamic acid,4-diamino-6-pteridinyl)methyl] methylamino]benzoyl]-, L-(+)-; L-Glutamic acid,4-diamino-6-pteridinyl)methyl]- methylamino]benzoyl]-; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)-(methyl)amino)benzamido)pentanedioic acid; GLUTAMIC ACID, N-(P-(((2,4-DIAMINO-6-PTERIDINYL)METHYL)METHYLAMINO)BENZOYL)-,L; L-Glutamic acid,N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-,hydrate(9ci); Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard; Methotrexate for system suitability, European Pharmacopoeia (EP) Reference Standard; Methotrexate, Pharmaceutical Secondary Standard; Certified Reference Material; N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino]benzoyl]-L-glutamic acid; (2S)-2-((4-(((2,4-DIAMINOPTERIDIN-6-YL)METHYL)(METHYL)AMINO)BENZOYL)AMINO)PENTANEDIOIC ACID; (2S)-2-[[[4-[(2,4-diamino-6-pteridinyl)methyl-methylamino]phenyl]-oxomethyl]amino]pentanedioic acid;hydrate; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]glutaric acid;hydrate; (2S)-2-[[4-[[2,4-bis(azanyl)pteridin-6-yl]methyl-methyl-amino]phenyl]carbonylamino]pentanedioic acid;hydrate; 102613-64-9
Click to Show/Hide
|
|||||
| Target(s) | Dihydrofolate reductase (DHFR) | |||||
| Structure |
|
|||||
| Formula | C20H22N8O5 |
|||||
| Isosmiles | CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
|
|||||
| InChIKey |
FBOZXECLQNJBKD-ZDUSSCGKSA-N
|
|||||
| IUPAC Name |
(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid
|
|||||
| Pharmaceutical Properties | Molecule Weight |
454.4 |
Polar area |
211 |
||
Complexity |
704 |
xlogp Value |
-1.8 |
|||
Heavy Count |
33 |
Rot Bonds |
9 |
|||
Hbond acc |
12 |
Hbond Donor |
5 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Half Maximal Inhibitory Concentration (IC50) | 0.002 | ug/mL |
P388 cells
|
Lymphoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.004 | ug/mL |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[2] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.005 | ug/mL |
A-549 cells
|
Lung adenocarcinoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.0061 | ug/mL |
T-cells
|
Normal
|
Undisclosed | [3] |
| Half Maximal Inhibitory Concentration (IC50) | 0.01 | ug/mL |
HT-29 cells
|
Colon adenocarcinoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.01 | ug/mL |
SK-MEL-28 cells (BRAF inhibitor resistant)
|
Cutaneous melanoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.027 | ug/mL |
PC-3 cells
|
Prostate carcinoma
|
[4] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.035 | ug/mL |
A-549 cells
|
Lung adenocarcinoma
|
[5] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.057 | ug/mL |
LOX IMVI cells
|
Melanoma
|
[4] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.16 | ug/mL |
T-47D cells
|
Invasive breast carcinoma
|
[6] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.16 | ug/mL |
T-47D cells
|
Invasive breast carcinoma
|
[7] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.23 | ug/mL |
HT-29 cells
|
Colon adenocarcinoma
|
[6] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.23 | ug/mL |
HT-29 cells
|
Colon adenocarcinoma
|
[7] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.24 | ug/mL |
NIH3T3 cells
|
Normal
|
[7] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.29 | ug/mL |
NCI-H23 cells
|
Lung adenocarcinoma
|
[4] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.32 | ug/mL |
Caco-2 cells
|
Colon adenocarcinoma
|
[6] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.32 | ug/mL |
Caco-2 cells
|
Colon adenocarcinoma
|
[7] | |
| Half Maximal Inhibitory Concentration (IC50) | 108 | ug/mL |
M21 cells
|
Melanoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 109 | ug/mL |
M21 cells
|
Melanoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 109 | ug/mL |
M21 cells
|
Melanoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 112 | ug/mL |
M21 cells
|
Melanoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 112 | ug/mL |
M21 cells
|
Melanoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 115 | ug/mL |
M21 cells
|
Melanoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 115 | ug/mL |
M21 cells
|
Melanoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 117 | ug/mL |
M21 cells
|
Melanoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 118 | ug/mL |
M21 cells
|
Melanoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 119 | ug/mL |
M21 cells
|
Melanoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 120 | ug/mL |
M21 cells
|
Melanoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 121 | ug/mL |
M21 cells
|
Melanoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 25 | ug/mL |
Caki-1 cells
|
Clear cell renal cell carcinoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 3 | ug/mL |
Caki-1 cells
|
Clear cell renal cell carcinoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 3.3 | ug/mL |
Caki-1 cells
|
Clear cell renal cell carcinoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 3.4 | ug/mL |
Caki-1 cells
|
Clear cell renal cell carcinoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 31.48 | ug/mL |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[9] | |
| Half Maximal Inhibitory Concentration (IC50) | 4.5 | ug/mL |
Caki-1 cells
|
Clear cell renal cell carcinoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 47.82 | ug/mL |
HT-29 cells
|
Colon adenocarcinoma
|
[9] | |
| Half Maximal Inhibitory Concentration (IC50) | >60 | ug/mL |
ZR-75-1 cells
|
Invasive breast carcinoma
|
[4] | |
| Half Maximal Inhibitory Concentration (IC50) | >60 | ug/mL |
Caki-1 cells
|
Clear cell renal cell carcinoma
|
[4] | |
| Half Maximal Inhibitory Concentration (IC50) | >60 | ug/mL |
DLD-1 cells
|
Colon adenocarcinoma
|
[4] | |
| Half Maximal Inhibitory Concentration (IC50) | >60 | ug/mL |
SNB-7 cells
|
Glioblastoma
|
[4] | |
| Half Maximal Inhibitory Concentration (IC50) | 0 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[10] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.005 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[11] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.6 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[12] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.6915 | nM |
NCI-H526 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[13] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.72 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[12] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.82 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[14] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.84 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[15] | |
| Half Maximal Inhibitory Concentration (IC50) | 1.18 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[12] | |
| Half Maximal Inhibitory Concentration (IC50) | 1.4 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[12] | |
| Half Maximal Inhibitory Concentration (IC50) | 1.983 | nM |
NCI-H1770 cells
|
Lung non-small cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HCT 116 cells
|
Colon carcinoma
|
[16] | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
H35 cells
|
Reuber hepatoma
|
[17] | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[18] | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
CCRF S-180 cells
|
Fibroblast sarcoma
|
[19] | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[20] | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[21] | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[22] | |
| Half Maximal Inhibitory Concentration (IC50) | 10.04 | nM |
HDLM-2 cells
|
Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.5 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[23] | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[24] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 100 | nM |
PC-3 cells
|
Prostate carcinoma
|
[25] | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[26] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 100 | nM |
NPC-TW01 cells
|
Nasopharyngeal carcinoma
|
[27] | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
TSU-Pr1 cells
|
Bladder carcinoma
|
[24] | |
| Half Maximal Inhibitory Concentration (IC50) | 1000 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[28] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
Hs 578T cells
|
Invasive breast carcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
SK-MEL-2 cells (MEK inhibitor-resistant)
|
Melanoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
SK-MEL-28 cells (BRAF inhibitor resistant)
|
Cutaneous melanoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
SK-MEL-28 cells (BRAF inhibitor resistant)
|
Cutaneous melanoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
NCI-H226 cells
|
Pleural epithelioid mesothelioma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
OVCAR-5 cells
|
Ovarian serous adenocarcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
SNB-75 cells
|
Glioblastoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
A498 cells
|
Renal carcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
BT-549 cells
|
Breast ductal carcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
EKVX cells
|
Non-small cell lung carcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
EKVX cells
|
Non-small cell lung carcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
HOP-92 cells
|
Non-small cell lung carcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
Malme-3M cells
|
Melanoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
Malme-3M cells
|
Melanoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
OVCAR-4 cells
|
Ovarian adenocarcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
RXF 393 cells
|
Renal carcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
TK-10 cells
|
Renal carcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
R2 cells
|
Normal
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 10000 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 10000 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 10000 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 10000 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 10000 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | >100000 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[33] | |
| Half Maximal Inhibitory Concentration (IC50) | >100000 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[34] | |
| Half Maximal Inhibitory Concentration (IC50) | >100000 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[35] | |
| Half Maximal Inhibitory Concentration (IC50) | >100000 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[10] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | >100000 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[33] | |
| Half Maximal Inhibitory Concentration (IC50) | >100000 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[10] | |
| Half Maximal Inhibitory Concentration (IC50) | >100000 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[36] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000000 | nM |
Sf21 cells
|
Normal
|
[37] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000000 | nM |
Sf21 cells
|
Normal
|
[37] | |
| Half Maximal Inhibitory Concentration (IC50) | 101.2 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1010.74 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 101624.87 | nM |
SK-MEL-2 cells (MEK inhibitor-resistant)
|
Melanoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 10166.71 | nM |
NCI-H2087 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10186.42 | nM |
BB49-HNC cells
|
Floor of mouth squamous cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10250 | nM |
NCI-H226 cells
|
Pleural epithelioid mesothelioma
|
[27] | |
| Half Maximal Inhibitory Concentration (IC50) | 1026.91 | nM |
ESS-1 cells
|
Endometrioid stromal sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10283.33 | nM |
HSC-3 cells
|
Oral squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10289.17 | nM |
LS-123 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 1050 | nM |
R1 cells
|
Normal
|
[38] | |
| Half Maximal Inhibitory Concentration (IC50) | 1053.35 | nM |
SK-HEP1 cells
|
Hepatoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1055.93 | nM |
SK-MEL3 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1056.05 | nM |
SK-MEL-24 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10592.33 | nM |
EFM-19 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 106 | nM |
D4 cells
|
Normal
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 106 | nM |
D4 cells
|
Normal
|
[40] | |
| Half Maximal Inhibitory Concentration (IC50) | 106 | nM |
D4 cells
|
Normal
|
[41] | |
| Half Maximal Inhibitory Concentration (IC50) | 106 | nM |
D4 cells
|
Normal
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 10625.59 | nM |
EC-GI-10 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10685.38 | nM |
C-33-A cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10692.98 | nM |
RMG-I cells
|
Ovarian clear cell adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 107.01 | nM |
MHH-ES-1 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10714.66 | nM |
GT3TKB cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10768.71 | nM |
KS-1 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1077.52 | nM |
KU-19-19 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10816.64 | nM |
S-117 cells
|
Thyroid gland sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10838.88 | nM |
CAL-120 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1084.08 | nM |
A204 cells
|
Rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10878.01 | nM |
NCI-H1355 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1090 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[42] | |
| Half Maximal Inhibitory Concentration (IC50) | 10940.48 | nM |
CAL-85-1 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1095.12 | nM |
UACC-893 cells
|
Breast carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 11.3 | nM |
FaDu cells
|
Hypopharyngeal squamous cell carcinoma
|
[43] | |
| Half Maximal Inhibitory Concentration (IC50) | 11.45 | nM |
HEL cells
|
Erythroleukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11.6 | nM |
MOLT-16 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11.6 | nM |
C2C12 cells
|
Normal
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 110 | nM |
HCC 2998 cells
|
Colon adenocarcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 110 | nM |
BGC-823 cells
|
Stomach adenocarcinoma
|
[26] | |
| Half Maximal Effective Concentration (EC50) | 1100 | nM |
Caco-2 cells
|
Colon adenocarcinoma
|
[44] | |
| Half Maximal Inhibitory Concentration (IC50) | 11007.14 | nM |
HOS cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11016.95 | nM |
SW982 cells
|
Biphasic synovial sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11032.73 | nM |
TE-6 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1110.7 | nM |
RERF-LC-MS cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11165.82 | nM |
NCI-H446 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11182.9 | nM |
MZ7-mel cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11195.57 | nM |
no-11 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11239.92 | nM |
SW900 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11256.58 | nM |
MPP-89 cells
|
Pleural epithelioid mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1127.99 | nM |
NCI-H727 cells
|
Lung carcinoid tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11348.21 | nM |
NMC-G1 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11376.93 | nM |
SW1463 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 114 | nM |
R2 cells
|
Normal
|
[45] | |
| Half Maximal Inhibitory Concentration (IC50) | 114 | nM |
R2 cells
|
Normal
|
[46] | |
| Half Maximal Inhibitory Concentration (IC50) | 114.24 | nM |
NCI-H1792 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11475.69 | nM |
H4 cells
|
Neuroglioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 115.06 | nM |
KYSE-150 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11519.79 | nM |
SW1573 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11589.88 | nM |
A-549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 116.29 | nM |
SW780 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11605.08 | nM |
TI-73 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 117.59 | nM |
LS-411N cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 117219.54 | nM |
SNB-78 cells
|
Glioblastoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1185.77 | nM |
COLO 205 cells
|
Colon adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 1186.96 | nM |
BALL-1 cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 119.4 | nM |
HCC 2998 cells
|
Colon adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 11979.96 | nM |
COLO-678 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11991.1 | nM |
HCC1954 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11992.34 | nM |
TE-5 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[47] | |
| Half Maximal Effective Concentration (EC50) | 12 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[48] | |
| Half Maximal Inhibitory Concentration (IC50) | 12 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[28] | |
| Half Maximal Inhibitory Concentration (IC50) | 12 | nM |
U-373MG ATCC cells
|
Astrocytoma
|
[49] | |
| Half Maximal Inhibitory Concentration (IC50) | 12.39 | nM |
LAMA-84 cells
|
Chronic myeloid leukemia
|
||
| Half Maximal Effective Concentration (EC50) | 12.5 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[50] | |
| Half Maximal Inhibitory Concentration (IC50) | 12.57 | nM |
697 cells
|
Childhood B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.6 | nM |
Ehrlich cells
|
Ehrlich ascites carcinoma
|
[15] | |
| Half Maximal Effective Concentration (EC50) | 12.8 | nM |
R30dm-CCRF-CEM cells
|
Lymphoblastic leukemia
|
[51] | |
| Half Maximal Inhibitory Concentration (IC50) | 120.5 | nM |
R2 cells
|
Normal
|
[52] | |
| Half Maximal Inhibitory Concentration (IC50) | 1206.31 | nM |
PFSK-1 cells
|
Primitive neuroectodermal tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12063.92 | nM |
MKN7 cells
|
Gastric tubular adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 121 | nM |
R2 cells
|
Normal
|
[40] | |
| Half Maximal Inhibitory Concentration (IC50) | 121 | nM |
R2 cells
|
Normal
|
[41] | |
| Half Maximal Inhibitory Concentration (IC50) | 121 | nM |
R2 cells
|
Normal
|
[53] | |
| Half Maximal Inhibitory Concentration (IC50) | 121.92 | nM |
COR-L23 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1212.05 | nM |
KYSE-180 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12169.67 | nM |
SK-UT-1 cells
|
Uterine corpus leiomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12192.83 | nM |
U-251MG cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12212.13 | nM |
8505C cells
|
Thyroid gland anaplastic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12292.46 | nM |
CP50-MEL-B cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12293.79 | nM |
MDA-MB-361 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 123.72 | nM |
COLO-800 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 123.89 | nM |
KARPAS-45 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12342.58 | nM |
SNU-387 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12385.3 | nM |
GCIY cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12419.8 | nM |
SF-295 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1245.29 | nM |
KYSE-140 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1250 | nM |
Jurkat cells
|
T acute lymphoblastic leukemia
|
[27] | |
| Half Maximal Inhibitory Concentration (IC50) | 12541.84 | nM |
BT474-M1 cells
|
Invasive breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1256.7 | nM |
L-428 cells
|
Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 126.38 | nM |
IST-MEL1 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12658.54 | nM |
TE-10 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12683.3 | nM |
Daoy cells
|
Medulloblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1270 | nM |
HEK293 cells
|
Normal
|
[54] | |
| Half Maximal Inhibitory Concentration (IC50) | 12792.55 | nM |
Becker cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12845.93 | nM |
T98G cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12884.1 | nM |
SW1116 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12952.45 | nM |
SW48 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12992.21 | nM |
HT-1080 cells (FAP expression)
|
Fibrosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12996.33 | nM |
SW 962 cells
|
Vulva lymphoid carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 13 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[55] | |
| Half Maximal Effective Concentration (EC50) | 13 | nM |
A-253 cells
|
Submandibular gland squamous cell carcinoma
|
[13] | |
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM |
WIL2 cells
|
Hereditary spherocytosis
|
[56] | |
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM |
WIL2 cells
|
Hereditary spherocytosis
|
[57] | |
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM |
WIL2 cells
|
Hereditary spherocytosis
|
[58] | |
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[20] | |
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM |
SW620 cells
|
Colon adenocarcinoma
|
[21] | |
| Half Maximal Inhibitory Concentration (IC50) | 13.1 | nM |
SW620 cells
|
Colon adenocarcinoma
|
[22] | |
| Half Maximal Inhibitory Concentration (IC50) | 13.23 | nM |
MHH-PREB-1 cells
|
B-cell non-Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.5 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[34] | |
| Half Maximal Effective Concentration (EC50) | 13.7 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[51] | |
| Half Maximal Effective Concentration (EC50) | 13.8 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[59] | |
| Half Maximal Effective Concentration (EC50) | 13.8 | nM |
Carcinoma cells
|
Carcinoma
|
Undisclosed | [59] |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 130 | nM |
HCT 116 cells
|
Colon carcinoma
|
[33] | |
| Half Maximal Inhibitory Concentration (IC50) | 130 | nM |
HCT 116 cells
|
Colon carcinoma
|
[35] | |
| Half Maximal Inhibitory Concentration (IC50) | 1300 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[60] | |
| Half Maximal Inhibitory Concentration (IC50) | 13077.3 | nM |
NCI-H747 cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13117.5 | nM |
NCI-H1623 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13184.17 | nM |
SK-N-FI cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13216.83 | nM |
CaR-1 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13217.74 | nM |
NCI-H1573 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1327.94 | nM |
HuO9 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 133.69 | nM |
HT cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1333.91 | nM |
MKN-28 cells
|
Gastric epithelial carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1350.19 | nM |
BT-20 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13690 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[61] | |
| Half Maximal Inhibitory Concentration (IC50) | 13715.83 | nM |
NCI-H2126 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13723.04 | nM |
IA-LM cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13744.35 | nM |
LoVo cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13761.05 | nM |
MFE-280 cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13798.38 | nM |
LB2241-RCC cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13812.21 | nM |
HCC1419 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13852.46 | nM |
OAW-28 cells
|
Ovarian serous cystadenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13852.68 | nM |
RXF 393 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13860.85 | nM |
SW756 cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1389.32 | nM |
NCI-H520 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 139.41 | nM |
QIMR-WIL cells
|
Acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13954.82 | nM |
T24 cells
|
Bladder carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 14 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[33] | |
| Half Maximal Effective Concentration (EC50) | 14 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[13] | |
| Half Maximal Effective Concentration (EC50) | 14 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[62] | |
| Half Maximal Effective Concentration (EC50) | 14 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[63] | |
| Half Maximal Effective Concentration (EC50) | 14 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[64] | |
| Half Maximal Inhibitory Concentration (IC50) | 14 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[10] | |
| Half Maximal Inhibitory Concentration (IC50) | 14.26 | nM |
L-363 cells
|
Plasma cell myeloma
|
||
| Half Maximal Effective Concentration (EC50) | 14.3 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[65] | |
| Half Maximal Effective Concentration (EC50) | 14.4 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[43] | |
| Half Maximal Effective Concentration (EC50) | 14.5 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[66] | |
| Half Maximal Effective Concentration (EC50) | 14.5 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[38] | |
| Half Maximal Effective Concentration (EC50) | 14.5 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[50] | |
| Half Maximal Effective Concentration (EC50) | 14.5 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[55] | |
| Half Maximal Effective Concentration (EC50) | 14.5 | nM |
A-253 cells
|
Submandibular gland squamous cell carcinoma
|
[43] | |
| Half Maximal Effective Concentration (EC50) | 14.5 | nM |
Carcinoma cells
|
Carcinoma
|
Undisclosed | [59] |
| Half Maximal Inhibitory Concentration (IC50) | 1400 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
[67] | |
| Half Maximal Inhibitory Concentration (IC50) | 1400 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[68] | |
| Half Maximal Inhibitory Concentration (IC50) | 1417.83 | nM |
SK-N-AS cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 142.31 | nM |
RT-112 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14289.74 | nM |
COLO-824 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1429.79 | nM |
COLO-829 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14315.86 | nM |
NCI-H810 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1433.68 | nM |
NCI-H1563 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 144.74 | nM |
SNU-C2B cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14500 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[69] | |
| Half Maximal Inhibitory Concentration (IC50) | 1461.39 | nM |
RCM-1 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14668.74 | nM |
OVCAR-5 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 147.16 | nM |
GI-ME-N cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14732.09 | nM |
NB69 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 148.36 | nM |
ES7 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14804.07 | nM |
NCI-H1648 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14936.26 | nM |
A101D cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1499.68 | nM |
SNU-5 cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14994.27 | nM |
HT-1376 cells
|
Bladder carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 15 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[63] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 15 | nM |
HCT 116 cells
|
Colon carcinoma
|
[70] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 15 | nM |
HCT 116 cells
|
Colon carcinoma
|
[71] | |
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
SW480 cells
|
Colon adenocarcinoma
|
[72] | |
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
SW480 cells
|
Colon adenocarcinoma
|
[28] | |
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
SW480 cells
|
Colon adenocarcinoma
|
[73] | |
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[74] | |
| Half Maximal Effective Concentration (EC50) | 15.5 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[59] | |
| Half Maximal Inhibitory Concentration (IC50) | 15.53 | nM |
KE-37 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 150 | nM |
SCC-25 cells
|
Squamous carcinoma
|
[75] | |
| Half Maximal Inhibitory Concentration (IC50) | 150.12 | nM |
KGN cells
|
Ovarian granulosa cell tumor
|
||
| Half Maximal Effective Concentration (EC50) | 1500 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[50] | |
| Half Maximal Effective Concentration (EC50) | 1500 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[55] | |
| Half Maximal Effective Concentration (EC50) | 1500 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[76] | |
| Half Maximal Inhibitory Concentration (IC50) | 1500 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[77] | |
| Half Maximal Inhibitory Concentration (IC50) | 151.43 | nM |
NCI-H2122 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15123.94 | nM |
M059J cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15223.85 | nM |
LB1047-RCC cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15299.19 | nM |
Calu-3 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 153.37 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15399.78 | nM |
GB-1 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1544.6 | nM |
OE19 cells
|
Esophageal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15592.84 | nM |
D-247MG cells
|
Gliosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15658.5 | nM |
SJSA-1 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1570 | nM |
EL4 cells
|
Thymoma
|
[3] | |
| Half Maximal Inhibitory Concentration (IC50) | 15764.74 | nM |
SW1783 cells
|
Anaplastic astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15777.17 | nM |
CW-2 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 158.09 | nM |
D-392MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15800 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[78] | |
| Half Maximal Inhibitory Concentration (IC50) | 15800.38 | nM |
RH-18 cells
|
Alveolar rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1586.64 | nM |
PSN1 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 15885.47 | nM |
HOP-18 cells
|
Non-small cell lung adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 159200 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
[79] | |
| Half Maximal Inhibitory Concentration (IC50) | 16 | nM |
5637 cells
|
Bladder carcinoma
|
[80] | |
| Half Maximal Effective Concentration (EC50) | 16 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[48] | |
| Half Maximal Inhibitory Concentration (IC50) | 16 | nM |
D54 cells
|
Glioblastoma
|
[49] | |
| Half Maximal Inhibitory Concentration (IC50) | 16.23 | nM |
CTB-1 cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16.25 | nM |
NOMO-1 cells
|
Acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16.39 | nM |
ES1 cells
|
Ewing sarcoma
|
||
| Half Maximal Effective Concentration (EC50) | 16.5 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[81] | |
| Half Maximal Inhibitory Concentration (IC50) | 1605 | nM |
A388 cells
|
Skin squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1605.3 | nM |
A673 cells
|
Rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16184.22 | nM |
A-427 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16198.91 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 162.12 | nM |
COLO-741 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1628.66 | nM |
NCI-H1650 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16327.49 | nM |
HuCCT-1 cells
|
Liver bile duct carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16346.99 | nM |
SNU-423 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16378.87 | nM |
ACN cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 164.44 | nM |
KM12 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16469.27 | nM |
SW626 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16566.67 | nM |
CAS-1 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16594.23 | nM |
GCT cells
|
Pleomorphic sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16653.88 | nM |
HOP-92 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1677.36 | nM |
NCI-H1437 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 168.35 | nM |
EW-1 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16832.29 | nM |
NB17 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16863.49 | nM |
COR-L105 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16965.94 | nM |
COLO-792 cells
|
Melanoma
|
||
| Half Maximal Effective Concentration (EC50) | 17 | nM |
FaDu cells
|
Hypopharyngeal squamous cell carcinoma
|
[13] | |
| Half Maximal Effective Concentration (EC50) | 17 | nM |
FaDu cells
|
Hypopharyngeal squamous cell carcinoma
|
[62] | |
| Half Maximal Effective Concentration (EC50) | 17 | nM |
FaDu cells
|
Hypopharyngeal squamous cell carcinoma
|
[63] | |
| Half Maximal Effective Concentration (EC50) | 17 | nM |
A-253 cells
|
Submandibular gland squamous cell carcinoma
|
[66] | |
| Half Maximal Effective Concentration (EC50) | 17.5 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[81] | |
| Half Maximal Effective Concentration (EC50) | 1700 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[48] | |
| Half Maximal Inhibitory Concentration (IC50) | 17057.62 | nM |
SK-MEL-2 cells (MEK inhibitor-resistant)
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 171.18 | nM |
DBTRG-05MG cells
|
Anaplastic astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1711.51 | nM |
LB831-BLC cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 173.89 | nM |
LCLC-103H cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17392.92 | nM |
DK-MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17407.18 | nM |
CAL-39 cells
|
Vulvar squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17429.65 | nM |
MDA-MB-175-VII cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1745.62 | nM |
LAN-6 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17536.83 | nM |
T84 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17567.12 | nM |
HCC38 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17719.93 | nM |
LB771-HNC cells
|
Head and neck squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17915.82 | nM |
UACC-62 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17962.51 | nM |
SF-126 cells
|
Glioblastoma
|
||
| Half Maximal Effective Concentration (EC50) | 18 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[13] | |
| Half Maximal Effective Concentration (EC50) | 18 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[62] | |
| Half Maximal Inhibitory Concentration (IC50) | 18 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[72] | |
| Half Maximal Inhibitory Concentration (IC50) | 18 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[28] | |
| Half Maximal Inhibitory Concentration (IC50) | 18 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[73] | |
| Half Maximal Inhibitory Concentration (IC50) | 180 | nM |
Fibroblast cells
|
Normal
|
Undisclosed | [82] |
| Half Maximal Inhibitory Concentration (IC50) | 1800 | nM |
H35R0.3 cells
|
MTX-resistant Reuber hepatoma
|
[17] | |
| Half Maximal Inhibitory Concentration (IC50) | 18000 | nM |
H35R0.3 cells
|
MTX-resistant Reuber hepatoma
|
[83] | |
| Half Maximal Inhibitory Concentration (IC50) | 18063.1 | nM |
SW1990 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 182.32 | nM |
U2OS cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18254.62 | nM |
TGBC11TKB cells
|
Gastric carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1827.33 | nM |
WM-115 cells
|
Melanoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 18365.38 | nM |
EKVX cells
|
Non-small cell lung carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 18560.6 | nM |
U-87MG ATCC cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18583.67 | nM |
COLO-679 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 186000 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[84] | |
| Half Maximal Inhibitory Concentration (IC50) | 18626.92 | nM |
SW948 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1878.58 | nM |
HMV-2 cells
|
Vaginal melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 188.36 | nM |
JAR cells
|
Gestational choriocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18849.42 | nM |
KP-N-YN cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1886.94 | nM |
KURAMOCHI cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1895.89 | nM |
A-172 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[85] | |
| Half Maximal Effective Concentration (EC50) | 19 | nM |
A-253 cells
|
Submandibular gland squamous cell carcinoma
|
[63] | |
| Half Maximal Inhibitory Concentration (IC50) | 19.35 | nM |
MV4-11 cells
|
Childhood acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.42 | nM |
J-RT3-T3-5 cells
|
T acute lymphoblastic leukemi
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.99 | nM |
RPMI-8866 cells
|
Chronic myelogenous leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19000 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[86] | |
| Half Maximal Inhibitory Concentration (IC50) | 19090.24 | nM |
SF539 cells
|
Gliosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 191 | nM |
UO-31 cells
|
Renal carcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 1913.34 | nM |
SW1417 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1914.59 | nM |
SHP-77 cells
|
Small cell lung carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 191866.87 | nM |
Hs 578T cells
|
Invasive breast carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 19229.51 | nM |
UACC-257 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1942.98 | nM |
M14 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19492.41 | nM |
GI-1 cells
|
Gliosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1952.97 | nM |
RPMI-7951 cells
|
Malignant melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19553.18 | nM |
MMAC-SF cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19598.22 | nM |
COLO-680N cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 196.34 | nM |
8305C cells
|
Thyroid gland anaplastic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 197.1 | nM |
MG-63 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 197000 | nM |
L1210 ( R81) cells
|
Mouse leukemia
|
[87] | |
| Half Maximal Inhibitory Concentration (IC50) | 1987.73 | nM |
A2058 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19971.26 | nM |
EGI-1 cells
|
Cholangiocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
PC-3 cells
|
Prostate carcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[86] | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[88] | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[89] | |
| Half Maximal Inhibitory Concentration (IC50) | 2.1 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[90] | |
| Half Maximal Inhibitory Concentration (IC50) | 2.5 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[91] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2.512 | nM |
OVCAR-4 cells
|
Ovarian adenocarcinoma
|
[92] | |
| Half Maximal Inhibitory Concentration (IC50) | 2.55 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[93] | |
| Half Maximal Inhibitory Concentration (IC50) | 2.7 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[94] | |
| Half Maximal Inhibitory Concentration (IC50) | 2.7 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[95] | |
| Half Maximal Inhibitory Concentration (IC50) | 2.7 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[96] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[88] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[97] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[98] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[41] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[45] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[53] | |
| Half Maximal Inhibitory Concentration (IC50) | 20.2 | nM |
HCC1599 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[99] | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[11] | |
| Half Maximal Inhibitory Concentration (IC50) | 20000 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[100] | |
| Half Maximal Inhibitory Concentration (IC50) | 20000 | nM |
SNU-C1 cells
|
Colon adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[90] | |
| Half Maximal Inhibitory Concentration (IC50) | 200000 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[57] | |
| Half Maximal Inhibitory Concentration (IC50) | 200000 | nM |
L1210 ( R81) cells
|
Mouse leukemia
|
[75] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20044.72 | nM |
NCI-H226 cells
|
Pleural epithelioid mesothelioma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 201.86 | nM |
LOX IMVI cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20210.19 | nM |
RCC10RGB cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20249.98 | nM |
DJM-1 cells
|
Skin squamous cell carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 2030 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[59] | |
| Half Maximal Inhibitory Concentration (IC50) | 20308.77 | nM |
NCI-H1703 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2053.52 | nM |
GOTO cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20653.8 | nM |
RXF 393 cells
|
Renal carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 20665.76 | nM |
IST-MES1 cells
|
Pleural epithelioid mesothelioma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20701.41 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 20774.97 | nM |
H-EMC-SS cells
|
Extraskeletal myxoid chondrosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 209.51 | nM |
CHL-1 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20900 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[101] | |
| Half Maximal Inhibitory Concentration (IC50) | 21 | nM |
IGROV-1 cells
|
Ovarian endometrioid adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 21 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[102] | |
| Half Maximal Inhibitory Concentration (IC50) | 21.17 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21.28 | nM |
DB cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21.56 | nM |
DoHH2 CDX model cells
|
Diffuse large B-cell lymphoma germinal center B-cell type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 210 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[26] | |
| Half Maximal Effective Concentration (EC50) | 2100 | nM |
R2 cells
|
Prostate carcinoma
|
Undisclosed | [81] |
| Half Maximal Inhibitory Concentration (IC50) | 211 | nM |
D4 cells
|
Normal
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 211 | nM |
D4 cells
|
Normal
|
[40] | |
| Half Maximal Inhibitory Concentration (IC50) | 211 | nM |
D4 cells
|
Normal
|
[41] | |
| Half Maximal Inhibitory Concentration (IC50) | 211 | nM |
D4 cells
|
Normal
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 211.57 | nM |
HCC 2998 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21149.62 | nM |
ABC-1 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 213.15 | nM |
SW 954 cells
|
Vulva squamous carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21406.55 | nM |
YH-13 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21578.06 | nM |
G-402 cells
|
Kidney neoplasm
|
||
| Half Maximal Inhibitory Concentration (IC50) | 216 | nM |
R2 cells
|
Normal
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 216 | nM |
R2 cells
|
Normal
|
[40] | |
| Half Maximal Inhibitory Concentration (IC50) | 216 | nM |
R2 cells
|
Normal
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 216 | nM |
R2 cells
|
Normal
|
[53] | |
| Half Maximal Inhibitory Concentration (IC50) | 21618.45 | nM |
NCI-H2342 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2162.7 | nM |
LC-2-ad cells
|
Lung adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 21677.04 | nM |
SNB-75 cells
|
Glioblastoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 217.95 | nM |
EW-22 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2180.64 | nM |
JVM-2 cells
|
Mantle cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21805.65 | nM |
8-MG-BA cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21842.66 | nM |
GMS-10 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21868.98 | nM |
D-566MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21900 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[61] | |
| Half Maximal Inhibitory Concentration (IC50) | 2197.1 | nM |
A-431 cells
|
Skin squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 22 | nM |
IGROV-1 cells
|
Ovarian endometrioid adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 22 | nM |
U-87MG ATCC cells
|
Glioblastoma
|
[49] | |
| Half Maximal Inhibitory Concentration (IC50) | 22 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[103] | |
| Half Maximal Inhibitory Concentration (IC50) | 22 | nM |
SW620 cells
|
Colon adenocarcinoma
|
[104] | |
| Half Maximal Inhibitory Concentration (IC50) | 22 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[103] | |
| Half Maximal Inhibitory Concentration (IC50) | 22 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[103] | |
| Half Maximal Inhibitory Concentration (IC50) | 22 | nM |
A375 cells
|
Amelanotic melanoma
|
[103] | |
| Half Maximal Inhibitory Concentration (IC50) | 22 | nM |
HEK293 cells
|
Normal
|
[103] | |
| Half Maximal Inhibitory Concentration (IC50) | 22 | nM |
A498 cells
|
Renal carcinoma
|
[103] | |
| Half Maximal Inhibitory Concentration (IC50) | 22.27 | nM |
HAL-01 cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 22.7 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[34] | |
| Half Maximal Inhibitory Concentration (IC50) | 2200 | nM |
Cancer cells
|
Cancer
|
Undisclosed | [54] |
| Half Maximal Inhibitory Concentration (IC50) | >22000 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[74] | |
| Half Maximal Inhibitory Concentration (IC50) | 220000 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[86] | |
| Half Maximal Inhibitory Concentration (IC50) | 220000 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[88] | |
| Half Maximal Inhibitory Concentration (IC50) | 220000 | nM |
L1210 ( R81) cells
|
Mouse leukemia
|
[89] | |
| Half Maximal Inhibitory Concentration (IC50) | 22246.22 | nM |
OCUB-M cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 223 | nM |
P388 cells
|
Lymphoma
|
[85] | |
| Half Maximal Inhibitory Concentration (IC50) | 2230.07 | nM |
LU-135 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2232.94 | nM |
ZR-75-30 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 224.12 | nM |
C8166 cells
|
Leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2246.41 | nM |
MKN-1 cells
|
Gastric carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 226.99 | nM |
UO-31 cells
|
Renal carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 2260 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[54] | |
| Half Maximal Inhibitory Concentration (IC50) | 22814.47 | nM |
A704 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2282.26 | nM |
Capan-2 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 22897.96 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 229 | nM |
NCI-H522 cells
|
Non-small cell lung carcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 22946.15 | nM |
D-502MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 22979.1 | nM |
KNS-42 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 23 | nM |
DU145 cells
|
Prostate carcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 23 | nM |
P388 cells
|
Lymphoma
|
[85] | |
| Half Maximal Inhibitory Concentration (IC50) | 23 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[10] | |
| Half Maximal Inhibitory Concentration (IC50) | 23044.27 | nM |
RVH-421 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23188.35 | nM |
NCI-H1993 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23230.8 | nM |
HCC1395 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23243 | nM |
YKG-1 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2340.4 | nM |
NCI-H1793 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2342.93 | nM |
KOSC-2 cells
|
Floor of mouth squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 235.41 | nM |
LU-139 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2355.05 | nM |
Malme-3M cells
|
Melanoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 23828.49 | nM |
D-423MG cells
|
Glioblastoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 24 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[70] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 24 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[71] | |
| Half Maximal Inhibitory Concentration (IC50) | 24 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[17] | |
| Half Maximal Inhibitory Concentration (IC50) | 24 | nM |
WIL2 cells
|
Hereditary spherocytosis
|
[105] | |
| Half Maximal Inhibitory Concentration (IC50) | 24 | nM |
WIL2 cells
|
Hereditary spherocytosis
|
[105] | |
| Half Maximal Inhibitory Concentration (IC50) | 24 | nM |
GUMBUS cells
|
Normal
|
[106] | |
| Half Maximal Inhibitory Concentration (IC50) | 24.78 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2400 | nM |
Cancer cells
|
Cancer
|
Undisclosed | [107] |
| Half Maximal Inhibitory Concentration (IC50) | 2408.07 | nM |
HT55 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2408.94 | nM |
NCI-H1304 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 242.58 | nM |
ES3 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24621.18 | nM |
OMC-1 cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24709.73 | nM |
Hs 578T cells
|
Invasive breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24775.05 | nM |
SNB-75 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24878.35 | nM |
T-47D cells
|
Invasive breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2490 | nM |
SW1116 cells
|
Colon adenocarcinoma
|
[79] | |
| Half Maximal Inhibitory Concentration (IC50) | 25 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[108] | |
| Half Maximal Inhibitory Concentration (IC50) | 25 | nM |
LCLC-103H cells
|
Lung large cell carcinoma
|
[80] | |
| Half Maximal Inhibitory Concentration (IC50) | 25 | nM |
WiDr cells
|
Colon adenocarcinoma
|
[72] | |
| Half Maximal Inhibitory Concentration (IC50) | 25 | nM |
WiDr cells
|
Colon adenocarcinoma
|
[28] | |
| Half Maximal Inhibitory Concentration (IC50) | 25 | nM |
WiDr cells
|
Colon adenocarcinoma
|
[73] | |
| Half Maximal Inhibitory Concentration (IC50) | 25 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[87] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 25 | nM |
P388 cells
|
Lymphoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 25 | nM |
SN12K1 cells
|
Lung metastasis of renal carcinoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 25 | nM |
P388/ADR cells
|
Lymphoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 25 | nM |
L1210 ( R81) cells
|
Mouse leukemia
|
[11] | |
| Half Maximal Inhibitory Concentration (IC50) | 25 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[35] | |
| Half Maximal Inhibitory Concentration (IC50) | 250 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[42] | |
| Half Maximal Inhibitory Concentration (IC50) | 250.03 | nM |
NCI-H1299 cells (MMAE resistant)
|
Lung large cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 250.03 | nM |
NCI-H522 cells
|
Non-small cell lung carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 250.58 | nM |
NCI-H358 cells
|
Minimally invasive lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2509.68 | nM |
NCI-H2052 cells
|
Pleural mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2513.95 | nM |
FTC-133 cells
|
Thyroid gland follicular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 25320 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[61] | |
| Half Maximal Inhibitory Concentration (IC50) | 2550 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[23] | |
| Half Maximal Inhibitory Concentration (IC50) | 25796.66 | nM |
NCI-H2029 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 25876.73 | nM |
NB6 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 26 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 26 | nM |
LOX IMVI cells
|
Melanoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 26 | nM |
LOX IMVI cells
|
Melanoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 26.5 | nM |
C2C12 cells
|
Normal
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 26.86 | nM |
Ramos-2G6-4C10 cells
|
Burkitt lymphoma
|
||
| Half Maximal Effective Concentration (EC50) | 2600 | nM |
R2 cells
|
Prostate carcinoma
|
Undisclosed | [38] |
| Half Maximal Inhibitory Concentration (IC50) | 2612.32 | nM |
HT-1197 cells
|
Recurrent bladder carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 2630 | nM |
R2-CCRF-CEM cells
|
Lymphoblastic leukemia
|
[51] | |
| Half Maximal Inhibitory Concentration (IC50) | 2637.41 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 265.63 | nM |
OCI-AML-2 cells
|
Adult acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 266.18 | nM |
NCI-H1155 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 266.22 | nM |
AsPC-1 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 26644.29 | nM |
BHT-101 cells
|
Anaplastic thyroid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 26849.52 | nM |
TK-10 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27 | nM |
PC-3 cells
|
Prostate carcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 27 | nM |
SCC-25 cells
|
Squamous carcinoma
|
[30] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 27.42 | nM |
LOX IMVI cells
|
Melanoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 27.99 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 27090 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[109] | |
| Half Maximal Inhibitory Concentration (IC50) | 2711.46 | nM |
NCI-H1838 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 273.84 | nM |
LU-99A cells
|
Lung giant cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2738.74 | nM |
IGR-1 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2791.73 | nM |
CAL-54 cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27940 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[110] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 27989.81 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 28 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 28 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 28 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 28 | nM |
UACC-62 cells
|
Melanoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 28 | nM |
UACC-62 cells
|
Melanoma
|
[29] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 28.51 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 28.58 | nM |
UACC-62 cells
|
Melanoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 28.6 | nM |
HEK293 cells
|
Normal
|
[102] | |
| Half Maximal Inhibitory Concentration (IC50) | 281.67 | nM |
OE33 cells
|
Barrett adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 287.21 | nM |
NCI-H1755 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 28780 | nM |
PC-3 cells
|
Prostate carcinoma
|
[61] | |
| Half Maximal Inhibitory Concentration (IC50) | 289.76 | nM |
NEC8 cells
|
Testicular embryonal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[29] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 29.24 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 29.58 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 29.58 | nM |
NBsusSR cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29089.52 | nM |
NCI-H2405 cells
|
Pleural mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2924.7 | nM |
C32 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2928.93 | nM |
MEL-HO cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 293.21 | nM |
NCI-H23 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 293.34 | nM |
5637 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2963.6 | nM |
SAOS-2 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2988.32 | nM |
C3A cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 299.05 | nM |
NCI-H28 cells
|
Pleural mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.119 | nM |
DEL/BVR cells
|
Anaplastic large cell lymphoma
|
||
| Half Maximal Effective Concentration (EC50) | 3.2 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[111] | |
| Half Maximal Inhibitory Concentration (IC50) | 3.28 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[96] | |
| Half Maximal Inhibitory Concentration (IC50) | 3.28 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[96] | |
| Half Maximal Inhibitory Concentration (IC50) | 3.4 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[112] | |
| Half Maximal Inhibitory Concentration (IC50) | 3.8 | nM |
WIL2 cells
|
Hereditary spherocytosis
|
[100] | |
| Half Maximal Inhibitory Concentration (IC50) | 3.9 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[113] | |
| Half Maximal Inhibitory Concentration (IC50) | 3.9 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[114] | |
| Half Maximal Inhibitory Concentration (IC50) | 3.92 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[115] | |
| Half Maximal Inhibitory Concentration (IC50) | 3.924 | nM |
ATN-1 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[25] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[88] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30.76 | nM |
DMS-273 cells
|
Small cell lung carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 300 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[79] | |
| Half Maximal Inhibitory Concentration (IC50) | 300 | nM |
LNCaP cells
|
Prostate carcinoma
|
[68] | |
| Half Maximal Effective Concentration (EC50) | 3000 | nM |
A-253 cells
|
Submandibular gland squamous cell carcinoma
|
[62] | |
| Half Maximal Inhibitory Concentration (IC50) | 3016.66 | nM |
EFO-21 cells
|
Ovarian serous cystadenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 309.51 | nM |
HD-MY-Z cells
|
Acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 31 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[49] | |
| Half Maximal Effective Concentration (EC50) | 31 | nM |
FaDu cells
|
Hypopharyngeal squamous cell carcinoma
|
[66] | |
| Half Maximal Inhibitory Concentration (IC50) | 31 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 31 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 31 | nM |
Colon 26 cells
|
Colon adenocarcinoma
|
[85] | |
| Half Maximal Inhibitory Concentration (IC50) | 31.21 | nM |
CGTH-W-1 cells
|
Thyroid gland squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 31.6 | nM |
HH cells
|
T-cell non-Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3148.74 | nM |
NTERA-2-cl-D1 cells
|
Teratocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3154.03 | nM |
KP-4 cells
|
Pancreatic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 317.51 | nM |
LK-2 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3175.41 | nM |
CAL-62 cells
|
Thyroid gland anaplastic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3188.89 | nM |
Huh-7 cells
|
Adult hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 32 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[86] | |
| Half Maximal Inhibitory Concentration (IC50) | 32 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[87] | |
| Half Maximal Inhibitory Concentration (IC50) | 32 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 32 | nM |
M14 cells
|
Melanoma
|
[29] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 32.14 | nM |
SN12C cells
|
Renal cell carcinoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 32.58 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 32.7 | nM |
HCT 116 cells
|
Colon carcinoma
|
[116] | |
| Half Maximal Inhibitory Concentration (IC50) | 3200 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[60] | |
| Half Maximal Inhibitory Concentration (IC50) | 3245.93 | nM |
MDA-MB-157 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3270 | nM |
COLO 205 cells
|
Colon adenocarcinoma
|
[117] | |
| Half Maximal Inhibitory Concentration (IC50) | 328.42 | nM |
NCI-H1048 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 33 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 33 | nM |
SW620 cells
|
Colon adenocarcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 33 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 33 | nM |
786-O cells
|
Renal cell carcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 33 | nM |
786-O cells
|
Renal cell carcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 33 | nM |
KM12 cells
|
Colon adenocarcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 33 | nM |
SR cells
|
Leukemia
|
[29] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 33.42 | nM |
M14 cells
|
Melanoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 33.5 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 33.65 | nM |
LXFL 529 cells
|
Non-small cell lung carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 334.47 | nM |
KYSE-450 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3363.25 | nM |
LN-405 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3396.1 | nM |
KP-N-YS cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 34.04 | nM |
786-O cells
|
Renal cell carcinoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 34.12 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 34.28 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 34.51 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 34.67 | nM |
HCT 116 cells
|
Colon carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 340 | nM |
DOGUM cells
|
Burkitt leukemia
|
[106] | |
| Half Maximal Inhibitory Concentration (IC50) | 3404.94 | nM |
Ca9-22 cells
|
Gingival squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3442.45 | nM |
HTC-C3 cells
|
Thyroid gland anaplastic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3450 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[117] | |
| Half Maximal Inhibitory Concentration (IC50) | 3470.42 | nM |
TE-9 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 35 | nM |
SF539 cells
|
Gliosarcoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 35 | nM |
SF539 cells
|
Gliosarcoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 35 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[99] | |
| Half Maximal Inhibitory Concentration (IC50) | 35 | nM |
L1210 ( R81) cells
|
Mouse leukemia
|
[89] | |
| Half Maximal Inhibitory Concentration (IC50) | 35 | nM |
HEK293 cells
|
Normal
|
[102] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 35.65 | nM |
DLD-1 cells
|
Colon adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 3506.5 | nM |
NH-12 cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3562.87 | nM |
NCI-H661 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 36 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 36 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 36 | nM |
SF-295 cells
|
Glioblastoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 36.28 | nM |
GR-ST cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 361.82 | nM |
RH-1 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3639.26 | nM |
KYSE-410 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3643.4 | nM |
UO-31 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 365.82 | nM |
NCI-H209 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 369.4 | nM |
KM-H2 cells
|
Hodgkin lymphoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 37.33 | nM |
SR cells
|
Leukemia
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 37.5 | nM |
SF539 cells
|
Gliosarcoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 37.55 | nM |
COLO-684 cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3705.51 | nM |
DMS-273 cells
|
Small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 373.19 | nM |
Ca-Ski cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3735.22 | nM |
MeWo cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 374.42 | nM |
VM-CUB-1 cells
|
Bladder carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 37411.06 | nM |
TK-10 cells
|
Renal carcinoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 38 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[33] | |
| Half Maximal Inhibitory Concentration (IC50) | 38 | nM |
SCC-15 cells
|
Squamous carcinoma
|
[75] | |
| Half Maximal Inhibitory Concentration (IC50) | 38.23 | nM |
A4-Fuk cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 38.28 | nM |
SF-295 cells
|
Glioblastoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 38.55 | nM |
ACHN cells
|
Renal adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 38.75 | nM |
BE-13 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 38.82 | nM |
SW620 cells
|
Colon adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 3851.21 | nM |
SK-MEL-30 cells
|
Cutaneous melanoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 38725.76 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 388.24 | nM |
TF-1 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3886.13 | nM |
PANC-08-13 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 389.18 | nM |
HCC70 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 39 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[29] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 39.81 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[92] | |
| Half Maximal Inhibitory Concentration (IC50) | 390.1 | nM |
IST-SL1 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3937.34 | nM |
CAMA-1 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3937.81 | nM |
SAS cells
|
Tongue squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 398 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 398.7 | nM |
HSC-2 cells
|
Oral cavity squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3983.99 | nM |
D-263MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.4 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[84] | |
| Half Maximal Inhibitory Concentration (IC50) | 4.5 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[118] | |
| Half Maximal Effective Concentration (EC50) | 4.5 | nM |
HuTu 80 cells
|
Duodenal adenocarcinoma
|
[111] | |
| Half Maximal Inhibitory Concentration (IC50) | 4.51 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[119] | |
| Half Maximal Inhibitory Concentration (IC50) | 4.6 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[75] | |
| Half Maximal Inhibitory Concentration (IC50) | 4.6 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[87] | |
| Half Maximal Inhibitory Concentration (IC50) | 4.6 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[105] | |
| Half Maximal Inhibitory Concentration (IC50) | 4.6 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[57] | |
| Half Maximal Inhibitory Concentration (IC50) | 4.8 | nM |
P388 cells
|
Lymphoma
|
[49] | |
| Half Maximal Inhibitory Concentration (IC50) | 4.819 | nM |
SK-NEP-1 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.967 | nM |
ML-2 cells
|
Acute myeloid leukemia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 40 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[25] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 40 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[120] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
ACHN cells
|
Renal adenocarcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
ACHN cells
|
Renal adenocarcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
Raji cells
|
EBV-related Burkitt lymphoma
|
[121] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
HBL-100 cells
|
Normal
|
[122] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 40.27 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 40.83 | nM |
NCI-H23 cells
|
Lung adenocarcinoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 40.93 | nM |
SF268 cells
|
Astrocytoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | >40000 | nM |
Colon 26 cells
|
Colon adenocarcinoma
|
[85] | |
| Half Maximal Inhibitory Concentration (IC50) | 4077.99 | nM |
Lu-65 cells
|
Lung giant cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 409.51 | nM |
MHH-NB-11 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4099.42 | nM |
J82 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 41.3 | nM |
P12-Ichikawa cells
|
T-cell leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 410 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[42] | |
| Half Maximal Inhibitory Concentration (IC50) | 415.94 | nM |
CAL-72 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 419000 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[123] | |
| Half Maximal Inhibitory Concentration (IC50) | 42 | nM |
KM12 cells
|
Colon adenocarcinoma
|
[30] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 42.95 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 422.2 | nM |
LCLC-97TM1 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 423.64 | nM |
M19-MEL cells
|
Melanoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 427.97 | nM |
SF268 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 428.37 | nM |
ES6 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 43 | nM |
NCI-H23 cells
|
Lung adenocarcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 43 | nM |
NCI-H23 cells
|
Lung adenocarcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 43.1 | nM |
BCPAP cells
|
Thyroid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 43.55 | nM |
P30-OHK cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 43.95 | nM |
KM-20L2 cells
|
Colon carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 4317.58 | nM |
Panc1005 cells
|
Pancreatic carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 432.51 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 4340.85 | nM |
NCI-H2291 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 435.31 | nM |
ES5 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4353.08 | nM |
LS-513 cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 44.06 | nM |
RXF 631 cells
|
Renal carcinoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 44.87 | nM |
MDA-N cells
|
Breast carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 4400 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[124] | |
| Half Maximal Inhibitory Concentration (IC50) | 4406.82 | nM |
BxPC-3 CDX model cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4414.18 | nM |
OVCAR-4 cells
|
Ovarian adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4454.56 | nM |
KYSE-520 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 447.6 | nM |
NB7 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 448.79 | nM |
NCI-H1666 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 45 | nM |
DU145 cells
|
Prostate carcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 45 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[28] | |
| Half Maximal Inhibitory Concentration (IC50) | 45.26 | nM |
769-P cells
|
Renal cell carcinom
|
||
| Half Maximal Inhibitory Concentration (IC50) | 45.26 | nM |
MS-1 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 450 | nM |
NCI-H522 cells
|
Non-small cell lung carcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 4532.64 | nM |
CAL-51 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4555.51 | nM |
NOS-1 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4585.3 | nM |
TGBC24TKB cells
|
Gallbladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4590.68 | nM |
SW837 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4600.2 | nM |
SW872 cells
|
Liposarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4618.39 | nM |
HuP-T3 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4671.36 | nM |
U-118-MG cells
|
Astrocytoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 47.64 | nM |
DU145 cells
|
Prostate carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 4744.18 | nM |
MEL-JUSO cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4762.89 | nM |
RKO cells
|
Colon carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 4775.29 | nM |
A498 cells
|
Renal carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 4791.54 | nM |
NCI-H510A cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 48 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 48.64 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[32] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 4864.07 | nM |
SK-MEL-28 cells (BRAF inhibitor resistant)
|
Cutaneous melanoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 4875.06 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 49.32 | nM |
KM12 cells
|
Colon adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 49220 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[110] | |
| Half Maximal Inhibitory Concentration (IC50) | 493.5 | nM |
Karpas-299 cells/Karpas BVR cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 496.54 | nM |
EW-24 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 498.56 | nM |
COLO-668 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 499.94 | nM |
EW-18 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[125] | |
| Half Maximal Inhibitory Concentration (IC50) | 5 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[126] | |
| Half Maximal Inhibitory Concentration (IC50) | 5.4 | nM |
CCRF S-180 cells
|
Fibroblast sarcoma
|
[15] | |
| Half Maximal Inhibitory Concentration (IC50) | 5.8 | nM |
SCC-7 cells
|
Squamous carcinoma
|
[23] | |
| Half Maximal Inhibitory Concentration (IC50) | 5.858 | nM |
ALL-PO cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[80] | |
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[17] | |
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
Vero C1008 cells
|
Normal
|
[127] | |
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
Vero C1008 cells
|
Normal
|
[127] | |
| Half Maximal Inhibitory Concentration (IC50) | 500.44 | nM |
SK-MEL-1 cells
|
Metastatic melanoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | >50000 | nM |
HCT 116 cells
|
Colon carcinoma
|
[16] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | >50000 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[16] | |
| Half Maximal Inhibitory Concentration (IC50) | 5020 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
[79] | |
| Half Maximal Inhibitory Concentration (IC50) | 5058.84 | nM |
VA-ES-BJ cells
|
Epithelioid sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5069.11 | nM |
SK-MES-1 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5079.77 | nM |
VMRC-RCZ cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 508.53 | nM |
KG-1 cells
|
Adult acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 510.68 | nM |
TE-12 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5100 | nM |
EL4 cells
|
Thymoma
|
[128] | |
| Half Maximal Inhibitory Concentration (IC50) | 518.65 | nM |
MSTO-211H cells
|
Pleural biphasic mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5199.57 | nM |
EPLC-272H cells
|
Lung mucoepidermoid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 52 | nM |
SF268 cells
|
Astrocytoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 52 | nM |
SF268 cells
|
Astrocytoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 52.11 | nM |
KYSE-270 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 52.38 | nM |
COLO 320HSR cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 521.99 | nM |
ES8 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5250 | nM |
COLO 320DM cells
|
Colon adenocarcinoma
|
[117] | |
| Half Maximal Inhibitory Concentration (IC50) | 5254.67 | nM |
HCC1806 cells
|
Breast squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5260.73 | nM |
NB13 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 532.72 | nM |
DSH1 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5320.83 | nM |
OS-RC-2 cells
|
Clear cell renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 534 | nM |
GUMBUS cells
|
Normal
|
[106] | |
| Half Maximal Inhibitory Concentration (IC50) | 5355.17 | nM |
NCI-H226 cells
|
Pleural epithelioid mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 536.88 | nM |
22RV1 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 54.54 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5512.18 | nM |
NB10 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 552.72 | nM |
Calu-6 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5528.57 | nM |
U266B1 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5554.32 | nM |
SN12C cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 563.79 | nM |
SBC-1 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 567 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[65] | |
| Half Maximal Inhibitory Concentration (IC50) | 567.41 | nM |
EFO-27 cells
|
Ovarian mucinous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 57.13 | nM |
EM-2 cells
|
Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 572.86 | nM |
PC-14 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5725.8 | nM |
BHY cells
|
Head and neck squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 580 | nM |
SCC-15 cells
|
Squamous carcinoma
|
[75] | |
| Half Maximal Inhibitory Concentration (IC50) | 587.74 | nM |
ME-180 cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5897.94 | nM |
MDA-MB-453 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 59.3 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[102] | |
| Half Maximal Inhibitory Concentration (IC50) | 59.8 | nM |
K5 cells
|
Thyroid gland papillary carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 590.2 | nM |
SNB-19 cells
|
Astrocytoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 5912.16 | nM |
KNS-62 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 595 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[48] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 59566.21 | nM |
OVCAR-4 cells
|
Ovarian adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 5961.88 | nM |
SW1710 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 597.37 | nM |
EW-11 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[41] | |
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[45] | |
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[53] | |
| Half Maximal Inhibitory Concentration (IC50) | 6.349 | nM |
BV-173 cells
|
Chronic myelogenous leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.6 | nM |
P388 cells
|
Lymphoma
|
[85] | |
| Half Maximal Inhibitory Concentration (IC50) | 6.92 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[129] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 60 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[25] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 60 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[120] | |
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[101] | |
| Half Maximal Inhibitory Concentration (IC50) | 60.61 | nM |
MC116 cells
|
B-cell non-Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 60000 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[130] | |
| Half Maximal Inhibitory Concentration (IC50) | 603.87 | nM |
AM-38 cells
|
Glioblastoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 603.95 | nM |
NCI-H322M cells
|
Minimally invasive lung adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 6032.26 | nM |
NCI-N87 cells
|
Gastric tubular adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6060.13 | nM |
MFM-223 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6096.15 | nM |
Capan-1 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 61.34 | nM |
AU565 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 61.38 | nM |
Caki-1 cells
|
Clear cell renal cell carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 6118.46 | nM |
HPAF-II cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6122.5 | nM |
NUGC-3 cells
|
Gastric carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6130 | nM |
Human umbilical vein endothelial cells(HUVEC)
|
Normal
|
Undisclosed | [22] |
| Half Maximal Inhibitory Concentration (IC50) | 614.54 | nM |
KINGS-1 cells
|
Anaplastic astrocytoma
|
||
| Half Maximal Effective Concentration (EC50) | 615 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[50] | |
| Half Maximal Inhibitory Concentration (IC50) | 6159.07 | nM |
KLE cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6165.83 | nM |
KYSE-70 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6174.42 | nM |
HO-1-N-1 cells
|
Buccal mucosa squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6187.82 | nM |
RPMI-2650 cells
|
Head and neck squamous cell carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 620 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[55] | |
| Half Maximal Inhibitory Concentration (IC50) | 628.13 | nM |
DMS-79 cells
|
Small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6289.16 | nM |
FaDu cells
|
Hypopharyngeal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 63 | nM |
U-251MG cells
|
Astrocytoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 63.77 | nM |
ONS-76 cells
|
Medulloblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6323.79 | nM |
639-V cells
|
Ureter urothelial carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6370.95 | nM |
HCC1569 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 639.01 | nM |
G-401 cells
|
Kidney Wilm's tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 643.3 | nM |
786-O cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6443.97 | nM |
SW1088 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6472.78 | nM |
HSC-4 cells
|
Cervical lymph node
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6477.48 | nM |
NCI-H292 cells
|
Lung mucoepidermoid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 65 | nM |
IGROV-1 cells
|
Ovarian endometrioid adenocarcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 65.73 | nM |
MN-60 cells
|
Burkitt lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 650.63 | nM |
NCI-H2452 cells
|
Pleural mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6518.61 | nM |
NCI-H630 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6562.65 | nM |
LXF-289 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6594.15 | nM |
SCC-25 cells
|
Squamous carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 66 | nM |
MC-38 cells
|
Mouse colon adenocarcinoma
|
[85] | |
| Half Maximal Inhibitory Concentration (IC50) | 66 | nM |
P388 cells
|
Lymphoma
|
[124] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 66.07 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
[32] | |
| Half Maximal Effective Concentration (EC50) | 660 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[59] | |
| Half Maximal Effective Concentration (EC50) | 660 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[76] | |
| Half Maximal Inhibitory Concentration (IC50) | 6600 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[86] | |
| Half Maximal Inhibitory Concentration (IC50) | 6600 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[87] | |
| Half Maximal Inhibitory Concentration (IC50) | 665.75 | nM |
YAPC cells
|
Pancreas carincoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6680.28 | nM |
NCI-H1693 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 671.49 | nM |
Caki-1 cells
|
Clear cell renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 672.92 | nM |
NCI-H441 cells
|
Lung papillary adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6786.83 | nM |
SKG-IIIa cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 680 | nM |
R1-CCRF-CEM cells
|
Lymphoblastic leukemia
|
[81] | |
| Half Maximal Inhibitory Concentration (IC50) | 6822.67 | nM |
LB2518-MEL cells
|
Melanoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 68548.82 | nM |
XF498 cells
|
Glioma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 686.05 | nM |
OC-314 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6867.75 | nM |
LS1034 cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6884.48 | nM |
HN cells
|
Cervical lymph node
|
||
| Half Maximal Inhibitory Concentration (IC50) | 689.55 | nM |
CFPAC-1 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 69.36 | nM |
SBC-5 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 69.37 | nM |
HT-3 cells
|
Cervical carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 69.57 | nM |
HC-1 cells
|
Hairy cell leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6924.74 | nM |
Detroit 562 cells
|
Pharyngeal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6942.67 | nM |
SH-4 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 695.81 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 69502.43 | nM |
BT-549 cells
|
Breast ductal carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 7 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[60] | |
| Half Maximal Inhibitory Concentration (IC50) | 7.05 | nM |
RS4
11 cells |
Adult B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.5 | nM |
SCC-25 cells
|
Squamous carcinoma
|
[75] | |
| Half Maximal Inhibitory Concentration (IC50) | 7.5 | nM |
SCC-25 cells
|
Squamous carcinoma
|
[23] | |
| Half Maximal Inhibitory Concentration (IC50) | 7.515 | nM |
SNU-1 cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.702 | nM |
NKM-1 cells
|
Acute myeloid leukemia
|
||
| Half Maximal Effective Concentration (EC50) | 7.9 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[76] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 70 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[16] | |
| Half Maximal Inhibitory Concentration (IC50) | 7031.92 | nM |
JEG-3 cells
|
Gestational choriocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7035.19 | nM |
UM-UC-3 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7058.21 | nM |
DoTc2-4510 cells
|
Cervix uteri
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7085.4 | nM |
HLE cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7085.95 | nM |
BB65-RCC cells
|
Renal cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 72 | nM |
NCI-H1299 cells (MMAE resistant)
|
Lung large cell carcinoma
|
[33] | |
| Half Maximal Inhibitory Concentration (IC50) | 72 | nM |
NCI-H1299 cells (MMAE resistant)
|
Lung large cell carcinoma
|
[34] | |
| Half Maximal Inhibitory Concentration (IC50) | 72 | nM |
NCI-H1299 cells (MMAE resistant)
|
Lung large cell carcinoma
|
[10] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 72.28 | nM |
U-251MG cells
|
Astrocytoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 72.3 | nM |
EW-13 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 720 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[69] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 7211.07 | nM |
HOP-92 cells
|
Non-small cell lung carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 722.99 | nM |
NY cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7240.89 | nM |
RO82-W-1 cells
|
Thyroid gland follicular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7279.89 | nM |
NCI-H1395 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 73 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[60] | |
| Half Maximal Inhibitory Concentration (IC50) | 7307.21 | nM |
no-10 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7394.01 | nM |
SK-MEL-28 cells (BRAF inhibitor resistant)
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 743.08 | nM |
SK-N-DZ cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7433.44 | nM |
SCC-9 cells
|
Tongue squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 75.01 | nM |
NB14 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 750 | nM |
HCT 116 cells
|
Colon carcinoma
|
[42] | |
| Half Maximal Inhibitory Concentration (IC50) | 7582.05 | nM |
DOK cells
|
Oral epithelial dysplasia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7598.39 | nM |
SK-LU-1 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7609.07 | nM |
SCC-4 cells
|
Tongue squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7617.41 | nM |
TGBC1TKB cells
|
Gallbladder undifferentiated carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7677.12 | nM |
CAL-33 cells
|
Tongue squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7687.12 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 77 | nM |
DAN-G cells
|
Pancreas adenocarcinoma
|
[80] | |
| Half Maximal Inhibitory Concentration (IC50) | 77.1 | nM |
CTV-1 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7704.6 | nM |
D283 Med cells
|
Medulloblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 772.41 | nM |
BPH-1 cells
|
Benign prostatic hyperplasia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 773.21 | nM |
TE-11 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7738.26 | nM |
ChaGo-K-1 cells
|
Bronchogenic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 778.72 | nM |
HCE-4 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 78 | nM |
NCI-ADR-RES cells
|
High grade ovarian serous adenocarcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 78 | nM |
NCI-ADR-RES cells
|
High grade ovarian serous adenocarcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 7802.43 | nM |
NCI-H1651 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7847.41 | nM |
CHP-212 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7859.67 | nM |
NCI-H2170 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 787.69 | nM |
HCT 116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 789.92 | nM |
NCI-H82 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 79.51 | nM |
ES4 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 790 | nM |
UACC-257 cells
|
Melanoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 7927.15 | nM |
Panc 03.27 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 8 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[65] | |
| Half Maximal Inhibitory Concentration (IC50) | 8.1 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[19] | |
| Half Maximal Effective Concentration (EC50) | 8.2 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[76] | |
| Half Maximal Inhibitory Concentration (IC50) | 8.5 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[131] | |
| Half Maximal Inhibitory Concentration (IC50) | 8.8 | nM |
143B cells
|
Osteosarcoma
|
[49] | |
| Half Maximal Inhibitory Concentration (IC50) | 8.9 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[102] | |
| Half Maximal Inhibitory Concentration (IC50) | 8.923 | nM |
A3-KAW cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 800 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[36] | |
| Half Maximal Effective Concentration (EC50) | 80000 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[44] | |
| Half Maximal Inhibitory Concentration (IC50) | 804.97 | nM |
GAMG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 805.09 | nM |
SCC-15 cells
|
Squamous carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 807.79 | nM |
NCI-H650 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8075.74 | nM |
HEC-1 cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 810.02 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8179.18 | nM |
HCC1937 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 820 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[77] | |
| Half Maximal Inhibitory Concentration (IC50) | 8206.87 | nM |
HT-144 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 82300 | nM |
Bel-7402 cells
|
Hepatoma
|
[26] | |
| Half Maximal Inhibitory Concentration (IC50) | 827.35 | nM |
SNU-449 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 833.44 | nM |
NCI-H596 cells
|
Lung adenosquamous carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 835.6 | nM |
UACC-257 cells
|
Melanoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 8356.61 | nM |
SK-PN-DW cells
|
Primitive neuroectodermal tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 84 | nM |
DOGUM cells
|
Burkitt leukemia
|
[106] | |
| Half Maximal Inhibitory Concentration (IC50) | 8417.44 | nM |
OAW-42 cells
|
Ovarian serous cystadenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8424.65 | nM |
MDA-MB-415 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8430.14 | nM |
CAL-12T cells
|
Lung non-small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8437.19 | nM |
RD cells
|
Rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 85 | nM |
H35R0.3 cells
|
MTX-resistant Reuber hepatoma
|
[83] | |
| Half Maximal Inhibitory Concentration (IC50) | 85.26 | nM |
ACHN cells
|
Renal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8502.33 | nM |
SiHa cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8569.61 | nM |
TCCSUP cells
|
Bladder carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 86.5 | nM |
PC-3 cells
|
Prostate carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 8690.38 | nM |
NCI-H1581 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 87 | nM |
SK-MEL-5 cells
|
Cutaneous melanoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 87 | nM |
SK-MEL-5 cells
|
Cutaneous melanoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 870 | nM |
COLO 205 cells
|
Colon adenocarcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 872.29 | nM |
MKN45 cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 875.84 | nM |
HCE-T cells
|
Nornal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8756.99 | nM |
TE-8 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 88.65 | nM |
LU-134-A cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8806.09 | nM |
GAK cells
|
Vulvar melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8833.46 | nM |
MZ1-PC cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8848.49 | nM |
HuP-T4 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 89.09 | nM |
HuO-3N1 cells
|
Osteosarcoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 89.95 | nM |
SK-MEL-5 cells
|
Cutaneous melanoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 894.75 | nM |
EW-16 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[56] | |
| Half Maximal Inhibitory Concentration (IC50) | 9 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[58] | |
| Half Maximal Inhibitory Concentration (IC50) | 9 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[19] | |
| Half Maximal Inhibitory Concentration (IC50) | 9 | nM |
Daoy cells
|
Medulloblastoma
|
[49] | |
| Half Maximal Inhibitory Concentration (IC50) | 9 | nM |
HuTu 80 cells
|
Duodenal adenocarcinoma
|
[73] | |
| Half Maximal Inhibitory Concentration (IC50) | 9.2 | nM |
Vero cells
|
Normal
|
[49] | |
| Half Maximal Inhibitory Concentration (IC50) | 9.5 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[49] | |
| Half Maximal Inhibitory Concentration (IC50) | 9.5 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[132] | |
| Half Maximal Inhibitory Concentration (IC50) | 9.8 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[102] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 90.78 | nM |
IGROV-1 cells
|
Ovarian endometrioid adenocarcinoma
|
[32] | |
| Half Maximal Effective Concentration (EC50) | 900 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[44] | |
| Half Maximal Inhibitory Concentration (IC50) | 9016.06 | nM |
BFTC-905 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 906 | nM |
H35R0.3 cells
|
MTX-resistant Reuber hepatoma
|
[133] | |
| Half Maximal Inhibitory Concentration (IC50) | 9083.99 | nM |
KALS-1 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 91.72 | nM |
KYSE-510 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9125.28 | nM |
MIA PaCa-2 cells (MSLN expression)
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9129.41 | nM |
EKVX cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 916.22 | nM |
OVCAR-5 cells
|
Ovarian serous adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 9183.52 | nM |
NCI-H2030 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 92.9 | nM |
NCI-ADR-RES cells
|
High grade ovarian serous adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 9200 | nM |
L6 cells
|
Normal
|
[134] | |
| Half Maximal Inhibitory Concentration (IC50) | 9208.64 | nM |
BFTC-909 cells
|
Renal pelvis urothelial carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 922.04 | nM |
NCI-H1092 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9250 | nM |
HCT 116 cells
|
Colon carcinoma
|
[61] | |
| Half Maximal Inhibitory Concentration (IC50) | 9281.87 | nM |
SW684 cells
|
Fibrosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9307.22 | nM |
647-V cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9373.67 | nM |
A498 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 94.28 | nM |
BB30-HNC cells
|
Head and neck squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9489 | nM |
AN3-CA cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9490 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[42] | |
| Half Maximal Inhibitory Concentration (IC50) | 9512.89 | nM |
MC-IXC cells
|
Askin tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9577.98 | nM |
LNCaP-Clone-FGC cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9583.54 | nM |
UMC-11 cells
|
Lung carcinoid tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 96.54 | nM |
MLMA cells
|
Hairy cell leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9614.03 | nM |
GP5d cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9632.43 | nM |
KNS-81-FD cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9644.3 | nM |
CAL-27 cells
|
Tongue adenosquamous carcinom
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9647.04 | nM |
DMS 114 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 97 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[104] | |
| Half Maximal Inhibitory Concentration (IC50) | 97.42 | nM |
KMOE-2 cells
|
Erythroleukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9704.11 | nM |
BEN cells
|
Lung non-small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9716.96 | nM |
NCI-H2347 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 980 | nM |
OVCAR-5 cells
|
Ovarian serous adenocarcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 9816.46 | nM |
A375 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9826.77 | nM |
MZ2-MEL cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 984.47 | nM |
SCH cells
|
Gastric choriocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 985 | nM |
R1-CCRF-CEM cells
|
Lymphoblastic leukemia
|
[51] | |
| Half Maximal Inhibitory Concentration (IC50) | 9897.78 | nM |
PA-1 cells
|
Ovarian mixed germ cell tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 99.44 | nM |
MEG-01 cells
|
Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 990 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[21] | |
| Half Maximal Inhibitory Concentration (IC50) | 990 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[22] | |
| Half Maximal Inhibitory Concentration (IC50) | 990 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[20] | |
| Half Maximal Inhibitory Concentration (IC50) | 996.16 | nM |
C2BBe1 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9990.71 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
IGF-MTX [Phase 1/2]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [135] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.34% | |||
B5-MTX [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [136] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
5.00 nM
|
Positive DLA-DR expression (DLA-DR+++/++) | ||
| Method Description |
For in vitro cytotoxicity assays, 1.25 x 105 cells were seeded on a 24-well plate. The cells were preincubated for 2 h with 20 M ZVAD. Then, 2 ug/mL of B5 or B5-MTX were added to the cells.
|
||||
| In Vitro Model | Canine lymphoma | CLBL-1 cells | CVCL_L322 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.